Mikhail Carrim

Mikhail Carrim

Auto-generated profile, based on publicly available information

Mikhail Carrim

Department of Rheumatology University College London Hospital, London, UK

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2026 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
MCMikhail Carrim
Mikhail Carrim
MSMuhammad R. A. Shipa
Muhammad R. A. Shipa
ABAicha Bouraoui
Aicha Bouraoui
TAToka Alsulaim
Toka Alsulaim
CFCorinne Fisher
Corinne Fisher
DSDebajit Sen
Debajit Sen
Background: Secondary drug failure to adalimumab remains a significant challenge in managing Juvenile Idiopathic Arthritis (JIA), with anti-adalimumab antibodies (ADA_ab) implicated as a potential mechanism. This study examines the relationship between ADA_ab formation and loss of response (LOR). Findings: In this retrospective, longitudinal study, a combination of conventional statistical methods and machine-learning algorithms were employed to investigate the association of adalimumab drug levels (ADA_drug) and ADA_ab, alongside clinical variables, on LOR among JIA patients treated between December 2016 and May 2024. LOR was defined as active disease. Among 184 patients, ADA_ab and ADA_drug emerged as the strongest predictors of LOR in random-forest analysis. In multiple logistic regression, higher ADA_ab levels were independently associated with increased risk of LOR (OR 1.18, 95% CI 1.08–1.29, p = 0.0003), while higher ADA_drug levels were associated with reduced risk (OR 0.81, 95% CI 0.68–0.95, p = 0.0103). An ADA_ab threshold of 69 AU/mL was associated with an eightfold increase in LOR (OR 8.04, 95% CI 2.8–26.1, p = 0.0002). Patients with high ADA_ab and undetectable ADA_drug had the highest risk of LOR (OR 28.24, 95% CI 7.11–111.63, p = 0.0001). Kaplan–Meier analysis demonstrated that 71% of patients with elevated ADA_ab experienced LOR within 12 months Conclusion: High ADA_ab levels are a significant predictor of LOR in JIA patients treated with adalimumab, particularly when coupled with low drug levels. We also report clinically meaningful one-year LOR rates. These findings support the use of therapeutic drug monitoring, which may help optimise treatment and improve long-term disease control.